Rapamycin, CCI-779, rilmenidine, lithium, liraglutide, neferine, and histone deacetylase inhibitors (HDIs) such as autophagy modulators are used as therapeutics against HD, which have various mechanisms, such as iInhibition and activation of mTORC1 and AMPK. Here, PRKAA1 is linked to Huntington disease.